Uveitis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028
Global Uveitis Drugs Market: Overview
A limited choice of commercial drugs composed of corticosteroid treatments, immunosuppresives and biologics is characteristic of the global uveitis drugs market. Uveitis (Uveitis) is a median eye inflammation (Uvea) known as the uvea tract. The uvea is made up of iris, ciliary and choroids. Certain prevalent causes of uveitis are autoimmune diseases, infection, injury, inflammatory diseases and surgeries. Uveitis-related common symptoms include eye pain, floating eye conditions, blurred vision, enhanced light sensitivity and redness in the eye. Uveitis happens in all age groups, but it mostly involves people aged 20 to 59. Corticoid therapy has historically formed the majority of global uveitis drugs market.
This market intelligence study on the global uveitis drugs market focusses on the prominent drivers impacting growth, market trend, possibilities, and limitations, if any. The report offers actionable insights on the key determinants and competitive landscape of the global uveitis drugs market.
Global Uveitis Drugs Market: Notable Developments
Some of the key developments influencing the global uveitis drugs market include:
Major players operating in the global uveitis drugs market include Allergan India Private Limited, Topivert Ltd, Bausch & Lomb Incorporated, pSivida Corp., HANALL, Ophthalix Inc., XOMA, and AbbVie Inc.
Global Uveitis Drugs Market Growth Dynamics
Increased aging population, increasing incidence of uveitis and associated complications have led to significant development of the global market for uveitis drugs. In addition, the implementation, rapid approval of pipeline drugs, increased investments in research and development into pharmaceuticals, and increasing public measures to minimize eye disorders also contribute to the growth of the global uveitis drugs market. Another important driver for the uveitis industry is the introduction of new drug delivery routes to improve the effectiveness of the drug.
Nevertheless, adverse effects of uveitis therapy drugs, such as watery eyes, irritations and others, could hinder development of the global uveitis drugs market. The market for uveitis drugs is likely to be further hampered by poor primary healthcare facilities, lack of knowledge of eye conditions, and an absence of health insurance in developing nations.
Asia Pacific to Experience Rapid Growth due to Supportive Governments
In the forecast period, North America is expected to account for a substantial share in the uveitis drugs market. The elevated incidence of related uveitis risk factors coupled with anticipated product approvals will lead to the increase in the uveitis drugs market in this region.
Asia Pacific, due to the greater incidence of uveitis in this region, is anticipated to experience the a swift growth of the uveitis drugs market during the forecasted era. A number of governments and private organizations have taken measures to raise disease awareness and to provide patients in the region with several therapy alternatives.
The study presents reliable qualitative and quantitative insights into:
The regional analysis covers:
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
Highlights of the report:
Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report